Tempo Therapeutics Closes $14.5M for MAP Technology

A surgeon can close a wound; the harder question is what the body builds in the space left behind. Tempo Therapeutics has closed a $14.5M financing to move its synthetic MAP biomaterial toward potential FDA clearance and commercialization, while exploring whether the same regenerative platform can support aesthetic applications.

The September 16 financing was led by Galaxy Sirius Partners, with participation from Johnson & Johnson through JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures, and other new and existing investors. It follows a 40-patient first-in-human study and a De Novo submission to the U.S. Food and Drug Administration, placing Tempo at the expensive handoff between an encouraging clinical result and a regulated commercial product.

What Happened

Tempo described the transaction as an oversubscribed $14.5M financing in its official announcement. Galaxy Sirius Partners led the round, and the company said proceeds will support the lead surgical reconstruction program through potential regulatory clearance and commercialization. A portion will also fund clinical work in regenerative aesthetics, including tissue changes associated with weight loss and healthy aging.

The SEC Form D adds important structure. Filed September 11 under Rule 506(b), it classifies the securities as debt and lists a $14.5M offering, with $14M sold to 43 investors and $500K remaining at that filing snapshot. Tempo announced the completed $14.5M financing 5 days later. The company did not disclose interest, maturity, security, conversion rights, valuation, or ownership terms.

This financing follows Tempo's $12M Series A equity round in March 2024, led by Galaxy-Sirius Partners and JJDC. Because Tempo did not label the new transaction a Series B and the regulatory filing identifies debt securities, describing it as a Series B would outrun the available evidence.

How MAP Technology Works

Tempo's Microporous Annealed Particle technology is a fully synthetic, flowable, porous biomaterial. The scaffold is designed to conform to irregular tissue spaces, allow cells and blood vessels to grow through its interconnected pores, and gradually resorb as the patient's own tissue replaces it. The commercial idea is unusually disciplined: the product should provide structure while healing is underway, then surrender that job to the tissue it helped organize.

MAP grew from academic work involving Tempo founders Westbrook Weaver, Donald Griffin, Dino Di Carlo, and Tatiana Segura. A 2015 Nature Materials paper described injectable microporous scaffolds assembled from microgel building blocks, showing how their pores could permit cell migration without waiting for the surrounding material to degrade first. Tempo has since concentrated the lead clinical program on surgical reconstruction and wound healing while preserving a broader platform strategy across regenerative medicine.

What the First Human Study Showed

The financing arrives after the publication of Tempo's randomized, controlled, multicenter first-in-human study. The trial included 40 patients with full-thickness wounds after Mohs surgery for non-melanoma skin cancer. Twenty-six patients received the MAP wound matrix, while 14 received a hydrocolloid dressing as the control.

The primary safety endpoint was met. The MAP group reached a favorable Wound Bed Score about 14 days earlier than the control group, and scar scores were significantly better at approximately 6 months. Granulation and overall wound-closure times were similar, which matters because the study supports a specific claim about safety, early wound-bed quality, and scarring rather than a broad promise that every stage of healing moved faster.

The evidence is meaningful and still early. Forty patients can establish a first clinical signal; they cannot settle performance across larger populations, different surgical settings, or aesthetic uses. Tempo has submitted its lead product through the FDA's De Novo pathway, but submission is not clearance, and the agency's review timeline and possible conditions remain undisclosed.

Leadership Changes Match the Company's Next Job

Tempo paired the financing with a leadership transition. Eric Richman, a director for the prior 2 years, became interim CEO and will work with the board and management team on regulatory, clinical, strategic, and commercial development. Co-founder and former CEO Westbrook Weaver moved into the CTO role, while co-founder Donald Griffin continues as CSO and a board member. Stephanie Deshayes remains VP of R&D.

The board is changing as well. Steven Sands, co-principal of Galaxy Sirius Partners, became chair; Erik Oros of Gideon Strategic Partners joined as a director; and a JJDC representative continues to serve. That configuration puts financing, commercialization, and strategic-transaction experience around the scientists carrying the MAP platform forward, which fits a company whose immediate risks now extend beyond invention.

Why the Financing Matters

Regenerative medicine often attracts attention through biological ambition. Tempo's lead program is making a different commercial wager: that carefully engineered synthetic material can guide the body's own repair process without requiring transplanted cells or a permanent implant. That could simplify important parts of manufacturing and delivery, but those advantages must still survive regulatory review, clinical scaling, physician adoption, and reimbursement.

The investor group also suggests continuity rather than a reset. Galaxy Sirius Partners and JJDC backed the 2024 Series A, and both are participating again after Tempo moved MAP into human testing. New participation from Gideon Strategic Partners and Mesa Verde Venture Partners broadens the capital base while placing investor representatives closer to governance.

The Work the Capital Now Has to Carry

Tempo has crossed an important boundary: MAP is no longer supported only by preclinical science. The company now has a published human study, a De Novo submission, a new interim CEO, and financing intended to carry the lead program toward a commercial decision. The next evidence will have to be operational as well as clinical, covering regulatory progress, manufacturing readiness, physician workflow, and a credible route to market.

The broader platform remains an option, not a finished product line. Regenerative aesthetics may expand the addressable opportunity, and MAP may eventually support more surgical and therapeutic uses, but the company's immediate value will be built in a narrower place: proving that a synthetic scaffold can help healthy tissue take over, and that Tempo can build the regulated business required to deliver it.